立体定向体部放疗治疗505例非脊柱骨转移后的病理性骨折与局部复发预测因素
本回顾性单中心研究纳入2011至2021年接受SBRT的373例患者共505处非脊柱骨转移,中位随访26.5个月,局部失败6、12、24个月累积发生率分别为5.7%、7.9%、12.6%,病理性骨折分别为3.8%、6.1%、10.9%;溶骨性转移、较低生物有效剂量和PTV≥54 cc预测局部失败,溶骨性、混合性病变和肋骨转移预测病理性骨折。
要点
- SBRT治疗非脊柱骨转移的局部控制率较高,病理性骨折发生率可接受。
- 溶骨性转移、较低生物有效剂量和PTV≥54 cc与局部失败风险升高相关。
- 溶骨性转移、混合性病变和肋骨转移与病理性骨折风险升高相关。
核心结论
- SBRT是治疗非脊柱骨转移的有效手段,影像学局部控制率高且病理性骨折发生率可接受。
- 研究识别出局部失败和病理性骨折的预测因素,可用于指导实践和试验设计。
研究设计与样本
- 回顾性单中心研究,纳入2011年至2021年接受SBRT的非脊柱骨转移患者,共373例患者505处病灶。
- 主要目标为评估影像学局部失败率,次要目标包括野内病理性骨折率、总生存和晚期≥3级毒性。
- 采用竞争风险分析评估局部失败和病理性骨折发生率,并行单因素和多因素回归分析预测因素。
主要发现
- 中位随访26.5个月,局部失败6、12、24个月累积发生率分别为5.7%、7.9%、12.6%。
- 病理性骨折6、12、24个月累积发生率分别为3.8%、6.1%、10.9%。
- 多因素分析显示,溶骨性转移(HR=2.18;p<0.01)、生物有效剂量每降低5 Gy10(HR=1.11;p=0.04)和PTV≥54 cc(HR=4.32;p<0.01)预测局部失败风险升高。
- 多因素分析显示,溶骨性转移(HR=3.43;p<0.01)、混合性(溶骨/成骨)病变(HR=2.70;p=0.04)和肋骨转移(HR=2.68;p<0.01)预测病理性骨折风险升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic Body Radiation Therapy (SBRT) is increasingly applied to treat non-spine bone metastases (NSBM) though data remains limited on this approach. In this retrospective study, we report outcomes and predictors of local failure (LF) and pathological fracture (PF) post-SBRT for NSBM using a mature single-institution database. METHODS: Patients with NSBM treated with SBRT between 2011 and 2021 were identified. The primary objective was to assess the rates of radiographic LF. Secondary objectives were to assess the rates of in-field PF, overall survival (OS), and late grade ≥ 3 toxicity. Competing risks analysis was used to assess rates of LF and PF. Univariable regression and multivariable regression (MVR) were performed to investigate predictors of LF and PF. RESULTS: A total of 373 patients with 505 NSBM were included in this study. Median follow-up was 26.5 months. The cumulative incidence of LF at 6, 12, and 24 months were 5.7%, 7.9%, and 12.6%, respectively. The cumulative incidence of PF at 6, 12, and 24 months were 3.8%, 6.1%, and 10.9%, respectively. Lytic NSBM (HR = 2.18; p < 0.01), a lower biologically effective dose (HR = 1.11 per 5 Gy10 decrease; p = 0.04), and a PTV ≥ 54 cc (HR = 4.32; p < 0.01) predicted for a higher risk of LF on MVR. Lytic NSBM (HR = 3.43; p < 0.01), mixed (lytic/sclerotic) lesions (HR = 2.70; p = 0.04), and rib metastases (HR = 2.68; p < 0.01) predicted for a higher risk of PF on MVR. CONCLUSION: SBRT is an effective modality to treat NSBM with high rates of radiographic local control with an acceptable rate of PF. We identify predictors of both LF and PF that can serve to inform practice and trial design.
引用
- Nguyen EK, Korol R, Ali S, et al. Predictors of pathologic fracture and local recurrence following stereotactic body radiation therapy to 505 non-spine bone metastases. Radiother Oncol. 2023. PMID: 37414253. doi:10.1016/j.radonc.2023.109792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。